1. Home
  2. ATHA vs ROMA Comparison

ATHA vs ROMA Comparison

Compare ATHA & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • ROMA
  • Stock Information
  • Founded
  • ATHA 2011
  • ROMA 2018
  • Country
  • ATHA United States
  • ROMA Hong Kong
  • Employees
  • ATHA N/A
  • ROMA N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • ROMA Savings Institutions
  • Sector
  • ATHA Health Care
  • ROMA Finance
  • Exchange
  • ATHA Nasdaq
  • ROMA Nasdaq
  • Market Cap
  • ATHA 21.0M
  • ROMA 22.9M
  • IPO Year
  • ATHA 2020
  • ROMA 2024
  • Fundamental
  • Price
  • ATHA $0.26
  • ROMA $2.08
  • Analyst Decision
  • ATHA Buy
  • ROMA
  • Analyst Count
  • ATHA 4
  • ROMA 0
  • Target Price
  • ATHA $11.25
  • ROMA N/A
  • AVG Volume (30 Days)
  • ATHA 214.5K
  • ROMA 112.3K
  • Earning Date
  • ATHA 05-09-2025
  • ROMA 12-16-2024
  • Dividend Yield
  • ATHA N/A
  • ROMA N/A
  • EPS Growth
  • ATHA N/A
  • ROMA N/A
  • EPS
  • ATHA N/A
  • ROMA N/A
  • Revenue
  • ATHA N/A
  • ROMA $1,029,120.00
  • Revenue This Year
  • ATHA N/A
  • ROMA N/A
  • Revenue Next Year
  • ATHA N/A
  • ROMA N/A
  • P/E Ratio
  • ATHA N/A
  • ROMA N/A
  • Revenue Growth
  • ATHA N/A
  • ROMA N/A
  • 52 Week Low
  • ATHA $0.22
  • ROMA $0.40
  • 52 Week High
  • ATHA $3.67
  • ROMA $2.05
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 45.40
  • ROMA 88.43
  • Support Level
  • ATHA $0.23
  • ROMA $1.75
  • Resistance Level
  • ATHA $0.30
  • ROMA $2.24
  • Average True Range (ATR)
  • ATHA 0.03
  • ROMA 0.25
  • MACD
  • ATHA 0.00
  • ROMA 0.06
  • Stochastic Oscillator
  • ATHA 37.12
  • ROMA 66.22

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.

Share on Social Networks: